A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the ...
TEL AVIV, Israel--(BUSINESS WIRE)--Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback